{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:03:34Z","timestamp":1791644614128,"version":"4.3.4"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Check point inhibitors (CPI) have improved survival of oncology patients but adverse effects that mimic autoimmune disorders have been reported. Our aim was describe the characteristics of immune\u2010related hepatitis (irH) and prognosis, and compared them to those of patients with autoimmune hepatitis (AIH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective study including all grade\u00a0\u2265\u00a03 (severe) irH diagnosed among 414 patients treated with CPI from 2016 to 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty\u2010eight cases of severe irH were recorded: 10 on anti\u2010CTLA\u20104\u00a0\u00b1\u00a0anti\u2010PD1\/PD\u2010L1 and 18 on anti\u2010PD1\/PD\u2010L1. Half were female, age 63\u00a0years, median time on CPI three cycles. Four (14.3%) presented acute liver injury or failure and one (3.6%) died as consequence. 94% presented normal immunoglobulin G (IgG). Six (21.4%) patients were retreated with CPI and none presented relapse or new immune\u2010related adverse events after a median cycles of 11 (range 6\u201036). Subjects with irH were older and had lower IgG values than a cohort of AIH (N\u00a0=\u00a038). Presentation tended to be more severe in AIH. Twenty\u2010five percent of irH and 84% AIH presented ANAs\u00a0\u2265\u00a01:80 (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a0.001). In irH Initial dose of corticosteroids was higher (60 vs 30\u00a0mg,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001) but duration shorter (2.3 vs 7\u00a0months,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001) and frequently in monotherapy (41.7% vs 91.3%,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Immune\u2010related hepatitis can lead to acute liver failure, with absence of increased values of IgG and ANAs. In contrast to autoimmune hepatitis, initial corticosteroids dose were higher, duration shorter with few requiring additional immunosuppression. Retreatment with CPI was not associated with recurrence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.14489","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T02:36:48Z","timestamp":1587695808000},"page":"1906-1916","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Immune\u2010related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-2052","authenticated-orcid":false,"given":"Mar","family":"Riveiro\u2010Barciela","sequence":"first","affiliation":[{"name":"Liver Unit Internal Medicine Department Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Barreira\u2010D\u00edaz","sequence":"additional","affiliation":[{"name":"Liver Unit Internal Medicine Department Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Vidal\u2010Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Liver Unit Internal Medicine Department Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mu\u00f1oz\u2010Couselo","sequence":"additional","affiliation":[{"name":"Oncology Department Instituto de Oncolog\u00eda Vall d\u2019Hebron (VHIO) Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mart\u00ednez\u2010Valle","sequence":"additional","affiliation":[{"name":"Systemic Autoimmune Diseases Unit Internal Medicine Department Hospital Universitario Vall d\u2019Hebron Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Viladomiu","sequence":"additional","affiliation":[{"name":"Liver Unit Internal Medicine Department Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"M\u00ednguez","sequence":"additional","affiliation":[{"name":"Liver Unit Internal Medicine Department Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Ortiz\u2010Velez","sequence":"additional","affiliation":[{"name":"Oncology Department Instituto de Oncolog\u00eda Vall d\u2019Hebron (VHIO) Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Castells","sequence":"additional","affiliation":[{"name":"Liver Unit Internal Medicine Department Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[{"name":"Liver Unit Internal Medicine Department Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Buti","sequence":"additional","affiliation":[{"name":"Liver Unit Internal Medicine Department Hospital Universitario Vall de Hebr\u00f3n Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.035"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.05.013"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.06.012"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13746"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30700-9"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.014"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0013-y"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2007.11.011"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80297-9"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260305"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.003"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.58"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23584"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.11.015"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000374"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.034"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0755"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1022"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fliv.14489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.14489","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.14489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:26:24Z","timestamp":1693891584000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.14489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/liv.14489"],"URL":"https:\/\/doi.org\/10.1111\/liv.14489","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"2020-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}